Um estudo duplo randomizado de 6 e 18 meses que avalia a segurança e a eficácia do Buntanetap em participantes com DA precoce (DUET-AD)
Um ensaio clínico duplo prospectivo, randomizado, controlado por placebo, duplo-cego de 6 meses e 18 meses que investiga a eficácia e segurança do Buntanetap no tratamento de participantes com doença de Alzheimer precoce
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
- Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
- Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
- What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.
Participants will:
- Take buntanetap/Posiphen or a placebo every day for 18 months
- Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
- Complete pre- and post-clinic visit phone calls
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85286
- MD First Research
-
Phoenix, Arizona, Estados Unidos, 85004
- Xenoscience
-
Scottsdale, Arizona, Estados Unidos, 85258
- Clinical Endpoints
-
-
California
-
Anaheim, California, Estados Unidos, 92805
- Advanced Research Center
-
Canoga Park, California, Estados Unidos, 91303
- Hope Clinical Research
-
Imperial, California, Estados Unidos, 92251
- Sun Valley Research
-
Los Angeles, California, Estados Unidos, 90095
- Mary S. Easton Center for Alzheimer's Research and Care, UCLA
-
Sacramento, California, Estados Unidos, 95816
- UC Davis Alzheimer's Disease Research Center
-
San Marcos, California, Estados Unidos, 92069
- The Neuron Clinic
-
-
Colorado
-
Basalt, Colorado, Estados Unidos, 81621
- Mountain Neurological Center
-
Englewood, Colorado, Estados Unidos, 80113
- CenExel Rocky Mountain
-
-
Connecticut
-
Norwalk, Connecticut, Estados Unidos, 06851
- Research Center for Clinical Trials
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Visionary Investigators Network
-
Boca Raton, Florida, Estados Unidos, 33487
- SFM Clinical Research
-
Clermont, Florida, Estados Unidos, 34711
- K2 Medical Research
-
Daytona Beach, Florida, Estados Unidos, 32114
- K2 Medical Research Daytona
-
Fort Myers, Florida, Estados Unidos, 33912
- Neuropsychiatric Research Center
-
Hallandale, Florida, Estados Unidos, 33009
- Velocity Clinical
-
Jacksonville, Florida, Estados Unidos, 32216
- Jacksonville Center for Clinical Research
-
Lady Lake, Florida, Estados Unidos, 32159
- K2 Medical Research
-
Lake Worth, Florida, Estados Unidos, 33462
- Headlands Research JEM
-
Lakeland, Florida, Estados Unidos, 33803
- Accel Research Sites Lakeland (Alcanza)
-
Maitland, Florida, Estados Unidos, 32751
- K2 Medical Research
-
Melbourne, Florida, Estados Unidos, 32940
- ClinCloud Clinical Research
-
Merritt Island, Florida, Estados Unidos, 32952
- Flourish Research/Merritt Island Medical Research
-
Miami, Florida, Estados Unidos, 33137
- Miami Jewish Health
-
Naples, Florida, Estados Unidos, 34102
- Aqualane Clinical Research
-
New Port Richey, Florida, Estados Unidos, 34652
- Suncoast Clinical Research
-
Orlando, Florida, Estados Unidos, 32832
- Conquest Research
-
Tampa, Florida, Estados Unidos, 33609
- Axiom Brain Health, LLC
-
Winter Park, Florida, Estados Unidos, 32789
- Conquest Research
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30030
- Accel Neurosciences
-
Gainesville, Georgia, Estados Unidos, 30501
- CARE (Center for Advanced Research & Education)
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96817
- Hawaii Pacific Neuroscience
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University Medical Center
-
Chicago, Illinois, Estados Unidos, 60611
- Re:Cognition Chicago
-
Chicago, Illinois, Estados Unidos, 60618
- Charter Research Chicago
-
Chicago, Illinois, Estados Unidos, 60640
- Great Lakes Clinical Trials/Flourish Research
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University
-
-
Indiana
-
Indianaopolis, Indiana, Estados Unidos, 46256
- JWM Research
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 37214
- Ascension via Christi Research
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Tandem Intermediate
-
-
Maryland
-
Pikesville, Maryland, Estados Unidos, 21208
- Headlands Research Pharmasite
-
-
Massachusetts
-
Foxborough, Massachusetts, Estados Unidos, 02035
- Neurology Center of New England, PC
-
Plymouth, Massachusetts, Estados Unidos, 02360
- Headlands Research Easter Massachusetts
-
Russells Mills, Massachusetts, Estados Unidos, 02747
- Mayflower Clinical
-
Springfield, Massachusetts, Estados Unidos, 01103
- Elixia MA
-
-
Michigan
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Quest Research Institute
-
-
Mississippi
-
Flowood, Mississippi, Estados Unidos, 39232
- Precise Research Center
-
-
Missouri
-
Chesterfield, Missouri, Estados Unidos, 63005
- Clinical Research Professionals - Headlands Research
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89121
- Oasis Clinical Trials LLC
-
-
New Jersey
-
Toms River, New Jersey, Estados Unidos, 08755
- Cenexel Advanced Medical Research of New Jersey (AMRI)
-
West Long Branch, New Jersey, Estados Unidos, 07764
- Advanced Clinical Institute
-
-
New York
-
Amherst, New York, Estados Unidos, 14226
- Dent Neurologic Institute
-
Brooklyn, New York, Estados Unidos, 11235
- SPRI
-
Lake Success, New York, Estados Unidos, 11042
- Neurological Associates of Long Island
-
New York, New York, Estados Unidos, 10003
- New York Neurology Associates
-
Staten Island, New York, Estados Unidos, 10314
- Richmond Behavioral Associates
-
Syracuse, New York, Estados Unidos, 13210
- Ichor Research
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Duke University
-
Matthews, North Carolina, Estados Unidos, 28105
- AMC Research/Flourish Research
-
-
Ohio
-
Beavercreek, Ohio, Estados Unidos, 45432
- American Clinical Research Center
-
Centerville, Ohio, Estados Unidos, 45459
- Valley Medical Research
-
Independence, Ohio, Estados Unidos, 44131
- Insight Clinical Trials
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97210
- Summit Headlands
-
-
Pennsylvania
-
Media, Pennsylvania, Estados Unidos, 19063
- Suburban Research Associates
-
Plymouth Meeting, Pennsylvania, Estados Unidos, 19462
- K2 Keystone
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Rhode Island Mood and Memory Research Institute
-
-
South Carolina
-
Summerville, South Carolina, Estados Unidos, 29486
- Palmetto Primary Care & Specialty Physicians
-
-
Tennessee
-
Cordova, Tennessee, Estados Unidos, 38018
- Neurology Clinic, P.C.
-
Nashville, Tennessee, Estados Unidos, 37204
- K2 Medical Research Nashville
-
-
Texas
-
Austin, Texas, Estados Unidos, 78757
- Senior Adults Specialty Research
-
Houston, Texas, Estados Unidos, 77094
- NeuroMind Clinical Trials
-
Round Rock, Texas, Estados Unidos, 78681
- Central Texas Neurology Associates
-
Wichita Falls, Texas, Estados Unidos, 76309
- Grayline Research Center
-
-
Vermont
-
Bennington, Vermont, Estados Unidos, 05201
- Memory Clinic, Inc.
-
-
Virginia
-
Arlington, Virginia, Estados Unidos, 22205
- Sana Research
-
Fairfax, Virginia, Estados Unidos, 22031
- Re:Cognition Fairfax
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.
-
Male or female, aged 55 - 85 years.
-
MMSE 20-28 at screening and baseline.
-
CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.
-
Positive for amyloid beta as defined by plasma p-tau217 level at screening.
-
Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
-
Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.
-
Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
-
Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
-
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
-
Intrauterine device (IUD),
-
Intrauterine hormone-releasing system (IUS),
-
Bilateral tubal occlusion,
-
Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),
-
Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
- Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
-
-
Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
- Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
- Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
- IUD,
- IUS,
- Bilateral tubal occlusion.
-
General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.
-
No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
-
Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.
- Cholinesterase inhibitors and/or memantine medication,
- Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
- Mood-stabilizing psychotropic agents including, but not limited to, lithium.
-
Adequate visual and hearing ability (physical ability to perform all the study assessments).
-
Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.
Exclusion Criteria:
-
Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.
-
History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
-
Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).
-
Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.
-
Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.
-
Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.
-
Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).
-
Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.
-
Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
-
Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
-
Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
-
Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
-
Participants with learning disability or developmental delay.
-
Participants whom the PI deems to be otherwise ineligible.
-
Participants with a known allergy to the investigational drug or any of its components.
Inactive ingredients of the investigational medicinal product:
- Silicified Microcrystalline Cellulose
- Dibasic Calcium Phosphate Dihydrate
- Mannitol
- Stearic Acid
- Hypromellosee (capsule shells structure)
- Titanium dioxide (opacifier of the capsule shells)
-
Participant is currently pregnant, breast-feeding, and/or lactating.
-
Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.
-
Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
Placebo capsule by mouth once daily for 18 months |
|
Experimental: buntanetap
|
30mg capsule by mouth once daily for 18 months |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Prazo: From screening to 6-month readout, to end of treatment at 18 months.
|
ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment. |
From screening to 6-month readout, to end of treatment at 18 months.
|
|
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Prazo: From screening to 6-month readout, to end of treatment at 18 months.
|
The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function. |
From screening to 6-month readout, to end of treatment at 18 months.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- ANVS-25001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .